Background

Three new truncation mutants have been discovered in primary human tumors and cell lines. These mutants may possess oncogenic activities and render some tumors resistant to certain inhibitors. These newly discovered mutants may be used as biomarkers for predicting patients? response to specific targeting agents.

Technology

Researchers at Stony Brook University discovered three new truncation mutants of EGFR in primary human tumors and cell lines. These mutations may be used as biomarkers for predicting a patients? response to anti-EGFR drugs, molecular diagnostic for micrometastasis/minimal residual disease monitoring or become new therapeutic targets for drug and antibody development.

Advantages

New EGFR truncation mutants may be used for predicting patients? response to EGFR targeting agents. - Could become new therapeutic targets for drug and antibody development.

Application

Biomarker for predicting patients? response to anti-EGFR drugs. - Therapeutic target for drug and antibody development.